| 主权项 |
1. A method of treating diabetes in a human subject, comprising the steps of:
isolating pancreatic islets of a transgenic animal and administering said isolated pancreatic islets of the transgenic animal into a human subject in need thereof, wherein said isolated pancreatic islets of the transgenic animal have the ability to normalize blood glucose levels in the human subject into which the islets are administered, wherein said transgenic animal is a transgenic animal whose genome comprises a recombinant nucleic acid comprising a polynucleotide sequence encoding a CTLA4 peptide fused to an immunoglobulin (“CTLA4 peptide-immunoglobulin fusion”) wherein said polynucleotide sequence is operably linked to an insulin promoter that results in expression of the CTLA4 peptide-immunoglobulin fusion, wherein said animal expresses the CTLA4 peptide-immunoglobulin fusion, wherein said expression is stable in offspring of said transgenic animal, wherein said animal exhibits, as a result of the expression of said CTLA4 peptide-immunoglobulin fusion, tissue-specific expression of the CTLA4 peptide-immunoglobulin fusion in pancreatic islets; and wherein after xenotransplantation of said transgenic pancreatic islets of said animal into a human subject, said transgenic pancreatic islets are protected from rejection by mature human immune system cells, normalize blood glucose levels in the human subject, and prevent re-occurrence of hyperglycemia. |
